ReviewInfection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases2021
Genetic comparison among various coronavirus strains for the identification of potential vaccine targets of SARS-CoV2.
Review in Infection, genetics and evolution : journal of molecular epidemiology and evolutionary genetics in infectious diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
62 citing papers in PubMed, 115 citations in OpenAlex.
- The influence of IFITM3 polymorphisms on susceptibility to SARS-CoV-2 infection and severity of COVID-19.Cytokine · 2021Trial
- Beyond the Mutation Abyss: Revisiting SARS-CoV-2 Receptor-Binding Domain Evolution from ACE2 Binding Optimization to Immune Epitope Remodeling.Pathogens (Basel, Switzerland) · 2026Article
- Cross-Reactive IgG Antibody Responses to SARS-CoV-2 in Older Adults Following Seasonal Coronavirus Infection in Jiangsu, China (2015-2017).Influenza and other respiratory viruses · 2026Article
- A Lung-Immune Dual-Humanized Mouse Using Cryopreserved Tissue Enables Infection and Immune Profiling of Human Common Cold Coronaviruses.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Heterologous betacoronavirus spike immunization in nonhuman primates elicits cross-reactive antibodies that neutralize both sarbeco- and merbecoviruses.bioRxiv : the preprint server for biology · 2026Article
- Article
- Lessons and concerns about the SARS-CoV-2/DENV co-infection.BMC infectious diseases · 2025Article
- Tracking SARS-CoV-2 seroprevalence in frontline healthcare workers at the beginning of COVID-19 pandemic and reliability of serological laboratory interpretation: a prospective cohort study.Virology journal · 2025Article
- Exploring the Intrinsic Structural Plasticity and Conformational Dynamics of Human Beta Coronavirus Spike Glycoproteins.Journal of chemical information and modeling · 2025Article
- Sustainable Polyphenol-Rich Extracts from Agricultural By-Products: Infectivity Inhibition Potential for Human Coronavirus 229E.Molecules (Basel, Switzerland) · 2025Article
- The S2 subunit of spike encodes diverse targets for functional antibody responses to SARS-CoV-2.PLoS pathogens · 2024Article
- Cross-Reactive Antibody Responses to Coronaviruses Elicited by SARS-CoV-2 Infection or Vaccination.Influenza and other respiratory viruses · 2024Article
- Article
- Review
- Immune responses of lung transplant recipients against SARS-CoV-2 and common respiratory coronaviruses: Evidence for pre-existing cross-reactive immunity.Transplant immunology · 2023Article
- SARS-CoV-2 and the DNA damage response.The Journal of general virology · 2023Review
- Clinical Utility of SARS-CoV-2 Serological Testing and Defining a Correlate of Protection.Vaccines · 2023Review
- A Review: The Potential Involvement of Growth Arrest-Specific 6 and Its Receptors in the Pathogenesis of Lung Damage and in Coronavirus Disease 2019.Microorganisms · 2023Review
- Phytochemical Profiling and Antiviral Activity of Green Sustainable Nanoparticles Derived fromPlants (Basel, Switzerland) · 2023Article
- The impact of pre-existing cross-reactive immunity on SARS-CoV-2 infection and vaccine responses.Nature reviews. Immunology · 2023Review
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
On-going pandemic pneumonia outbreak COVID-19 has raised an urgent public health issue worldwide impacting millions of people with a continuous increase in both morbidity and mortality. The causative agent of this disease is identified and named as SARS-CoV2 because of its genetic relatedness to SARS-CoV species that was responsible for the 2003 coronavirus outbreak. The immense spread of the disease in a very small period demands urgent development of therapeutic and prophylactic interventions for the treatment of SARS-CoV2 infected patients. A plethora of research is being conducted globally on this novel coronavirus strain to gain knowledge about its origin, evolutionary history, and phylogeny. This review is an effort to compare genetic similarities and diversifications among coronavirus strains, which can hint towards the susceptible antigen targets of SARS-CoV2 to come up with the potential therapeutic and prophylactic interventions for the prevention of this public threat.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.